Bank of America Corp
Change company Symbol lookup
Select an option...
BAC Bank of America Corp
CX Cemex SAB de CV
TPRE Third Point Reinsurance Ltd
KVHI KVH Industries Inc
SUP Superior Industries International Inc
FB Facebook Inc
V Visa Inc
FL Foot Locker Inc
DPZ Domino's Pizza Inc
CTMX CytomX Therapeutics Inc
Go

Financials : Banks | Large Cap Value
Company profile

Bank of America Corporation is a bank holding company and a financial holding company. The Company is a financial institution, serving individual consumers and others with a range of banking, investing, asset management and other financial and risk management products and services. The Company, through its banking and various non-bank subsidiaries, throughout the United States and in international markets, provides a range of banking and non-bank financial services and products through four business segments: Consumer Banking, which comprises Deposits and Consumer Lending; Global Wealth & Investment Management, which consists of two primary businesses: Merrill Lynch Global Wealth Management and U.S. Trust, Bank of America Private Wealth Management; Global Banking, which provides a range of lending-related products and services; Global Markets, which offers sales and trading services, and All Other, which consists of equity investments, residual expense allocations and other.

Premarket

Last Trade
Delayed
$28.16
-0.97 (-3.33%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$29.13
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
13,656

10-day average volume:
56,916,253
13,656

Revolution Medicines shares soar 85% in trading debut after IPO priced at top end of range

11:20 am ET February 13, 2020 (MarketWatch)
Print

Shares of Revolution Medicines Inc. (RVMD), a clinical-stage oncology company, soared 85% Thursday in their trading debut, after underwriters priced the initial public offering at the top end of a revised range. The Redwood City, California-based company sold 14 million shares priced at $17 each to raise $238 million. The deal was upsized from an earlier plan to offer 10 million shares priced at $14 to $16 each. JPMorgan, Cowen, SVB Leerink and Guggenheim were underwriters on the deal. Proceeds will be used to fund R&D, to move toward clinical trials for some candidates and for general corporate purposes. "We are a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways," says the prospectus.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

February 13, 2020 11:20 ET (16:20 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.